Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): A randomised, international, multicentre phase 2 trial

The Lancet Oncology

Volumn 16, Issue 16, 2015, Pages 1651-1658

  Stahel, Rolf A ^a   Riesterer, Oliver ^a   Xyrafas, Alexandros ^b   Opitz, Isabelle ^a   Beyeler, Michael ^b   Ochsenbein, Adrian ^c   Früh, Martin ^d   Cathomas, Richard ^e   Nackaerts, Kristiaan ^f   Peters, Solange ^g   Mamot, Christoph ^h   Zippelius, Alfred ⁱ   Mordasini, Carlo ^j   Caspar, Clemens B ^k   Eckhardt, Katrin ^b   Schmid, Ralph A ^c   Aebersold, Daniel M ^c   Gautschi, Oliver ^c   Nagel, Wolfgang ^d   Töpfer, Michael ^d   Krayenbuehl, Jerome ^a   Ribi, Karin ^l   Ciernik, llja F ^m   Weder, Walter ^a   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h CANTONAL HOSPITAL AARAU   (Switzerland)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^j Spital Bern Tiefenau   (Switzerland)

^k Cantonal Hospital Baden   (Switzerland)

^l International Breast Cancer Study Group   (Switzerland)

^m DESSAU MEDICAL CENTER   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CARBOPLATIN; CISPLATIN; CREATININE; PEMETREXED; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BELGIUM; BRAIN ISCHEMIA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGITIS; FAINTNESS; FATIGUE; FEMALE; FOLLOW UP; GERMANY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LOCAL RECURRENCE FREE SURVIVAL; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; MOOD DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PNEUMONIA; PRIORITY JOURNAL; PULMONARY ASPIRATION; RADIATION DERMATITIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWITZERLAND; THROMBOCYTOPENIA; THROMBOSIS; TINNITUS; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; ADVERSE EFFECTS; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; EUROPE; KAPLAN MEIER METHOD; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MESOTHELIOMA; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PLEURAL NEOPLASMS; PROPORTIONAL HAZARDS MODEL; RADIOTHERAPY DOSAGE; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PEMETREXED; PLEURAL NEOPLASMS; PNEUMONECTOMY; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84960841231     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00208-9     Document Type: Article

References (24)

1. Pelucchi C, Malvezzi M, La Vecchia C, Levi F, Decarli A, Negri E The mesothelioma epidemic in western Europe: an update. Br J Cancer 2004, 90:1022-1024.
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
3. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004, 22:3451-3457.
4. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007, 18:1196-1202.
5. Federico R, Adolfo F, Giuseppe M, et al. Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma. BMC Cancer 2013, 13:22.
6. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27:3007-3013.
7. van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010, 36:1362-1369.
8. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011, 12:763-772.
9. Weder W, Stahel RA, Baas P, et al. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 2011, 12:1093-1094.
10. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001, 122:788-795.
11. Rusch VW A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996, 14:1-12.
12. Herson J, Carter SK Calibrated phase II clinical trials in oncology. Stat Med 1986, 5:441-447.
13. van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010, 36:1362-1369.
14. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999, 117:54-63.
15. Gomez DR, Hong DS, Allen PK, et al. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol 2013, 8:238-245.
16. Cao CQ, Yan TD, Bannon PG, McCaughan BC A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 2010, 5:1692-1703.
17. Bovolato P, Casadio C, Bille A, et al. Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol 2014, 9:390-396.
18. Rusch VW Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach. Ann Cardiothorac Surg 2012, 1:523-531.
19. Bolukbas S, Eberlein M, Schirren J Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma. J Thorac Oncol 2012, 7:900-905.
20. Taioli E, Wolf AS, Flores RM Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg 2015, 99:472-480.
21. Rimner A, Spratt DE, Zauderer MG, et al. Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2014, 90:394-401.
22. Sugarbaker DJ, Gill RR, Yeap BY, et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg 2013, 145:955-963.
23. Opitz I, Lauk O, Meerang M, et al. MO 14.05 intracavitary cisplatin-fibrin chemotherapy after resection for malignant pleural mesothelioma patients (influence-meso)-preliminary results. J Thorac Oncol 2013, 8(suppl 2):343.
24. Stahel RA, Weder W, Felley-Bosco E, et al. Searching for targets for the systemic therapy of mesothelioma. Ann Oncol 2015, 26:1649-1660.